Journal article
Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome
Abstract
BACKGROUND: Imbalances in gut luminal bacteria may contribute to the pathogenesis of irritable bowel syndrome (IBS).
AIM: To explore select bacteriological and anti-inflammatory effects of mesalazine (mesalamine; 5-aminosalicylic acid or 5ASA) and their relation to potential therapeutic effects in IBS.
Authors
Andrews CN; Griffiths TA; Kaufman J; Vergnolle N; Surette MG; Rioux KP
Journal
Alimentary Pharmacology & Therapeutics, Vol. 34, No. 3, pp. 374–383
Publisher
Wiley
Publication Date
August 2011
DOI
10.1111/j.1365-2036.2011.04732.x
ISSN
0269-2813